# Checkmate Pharmaceuticals Inc. (CMPI)

Source: https://www.quantisnow.com/company/CMPI
Generated: 2026-11-02T10:13:41.373Z

- Ticker: CMPI
- Exchange: NASDAQ
- Sector: Consumer Durables
- Industry: Specialty Chemicals
- IPO year: 2020
- Website: checkmatepharma.com

## About

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

## Latest CMPI news and filings

- 2024-10-30 10:00 UTC [Axonis Therapeutics Announces $115 Million Series A Financing](https://www.quantisnow.com/insight/axonis-therapeutics-announces-115-million-series-a-financing-5742507)
- 2024-08-01 12:00 UTC [venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies](https://www.quantisnow.com/insight/venbio-raises-528-million-venture-capital-fund-focused-on-life-5637065)
- 2022-06-10 12:37 UTC [SEC Form 15-12B] [SEC Form 15-12B filed by Checkmate Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-15-12b-filed-by-checkmate-pharmaceuticals-inc-3014179)
- 2022-06-07 20:15 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Checkmate Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-checkmate-pharmaceuticals-inc-amendment-3000631)
- 2022-06-07 15:39 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Checkmate Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-checkmate-pharmaceuticals-inc-amendment-2999061)
- 2022-06-03 19:01 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Checkmate Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-checkmate-pharmaceuticals-inc-amendment-2986658)
- 2022-06-03 15:40 UTC [SEC Schedule 13D] [SEC Form SC 13D filed by Checkmate Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-sc-13d-filed-by-checkmate-pharmaceuticals-inc-2985759)
- 2022-06-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Checkmate Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-checkmate-pharmaceuticals-inc-2977296)
- 2022-06-02 09:29 UTC [Market Insight] [Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers  $2.5M Milestone Payment to XOMA](https://www.quantisnow.com/insight/completion-of-the-acquisition-of-checkmate-pharmaceuticals-by-regeneron-pharmaceuticals-2977037)
- 2022-05-31 21:21 UTC [SEC Form 25-NSE filed by Checkmate Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-checkmate-pharmaceuticals-inc-2968914)
- 2022-05-31 14:14 UTC [SEC Form 4] [SEC Form 4 filed by Powell Michael](https://www.quantisnow.com/insight/sec-form-4-filed-by-powell-michael-2964822)
- 2022-05-31 14:12 UTC [SEC Form 4] [SEC Form 4 filed by Flaherty Keith T.](https://www.quantisnow.com/insight/sec-form-4-filed-by-flaherty-keith-t-2964801)
- 2022-05-31 14:11 UTC [SEC Form 4] [SEC Form 4 filed by Isacoff Oren](https://www.quantisnow.com/insight/sec-form-4-filed-by-isacoff-oren-2964792)
- 2022-05-31 14:08 UTC [SEC Form 4] [SEC Form 4 filed by Colabuono Peter](https://www.quantisnow.com/insight/sec-form-4-filed-by-colabuono-peter-2964770)
- 2022-05-31 14:06 UTC [SEC Form 4] [SEC Form 4 filed by Yan Joy](https://www.quantisnow.com/insight/sec-form-4-filed-by-yan-joy-2964761)
- 2022-05-31 14:05 UTC [SEC Form 4] [SEC Form 4 filed by Dolski Robert](https://www.quantisnow.com/insight/sec-form-4-filed-by-dolski-robert-2964753)
- 2022-05-31 14:04 UTC [SEC Form 4] [SEC Form 4 filed by Wooldridge James](https://www.quantisnow.com/insight/sec-form-4-filed-by-wooldridge-james-2964743)
- 2022-05-31 14:02 UTC [SEC Form 4] [SEC Form 4 filed by Wigginton Jon Marc](https://www.quantisnow.com/insight/sec-form-4-filed-by-wigginton-jon-marc-2964727)
- 2022-05-31 14:02 UTC [SEC Form 4] [SEC Form 4 filed by Fuhrman Alan](https://www.quantisnow.com/insight/sec-form-4-filed-by-fuhrman-alan-2964721)
- 2022-05-31 13:59 UTC [SEC Form 4] [SEC Form 4 filed by Bash Alan](https://www.quantisnow.com/insight/sec-form-4-filed-by-bash-alan-2964604)
- 2022-05-31 13:26 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Checkmate Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-checkmate-pharmaceuticals-inc-2964406)
- 2022-05-31 13:26 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Checkmate Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-checkmate-pharmaceuticals-inc-2964403)
- 2022-05-31 13:25 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Checkmate Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-checkmate-pharmaceuticals-inc-2964398)
- 2022-05-31 13:25 UTC [SEC Form POS AM filed by Checkmate Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-checkmate-pharmaceuticals-inc-2964395)
- 2022-05-31 13:16 UTC [SEC Form 8-K] [Checkmate Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/checkmate-pharmaceuticals-inc-filed-sec-form-8-k-completion-of-acquisition-2964329)
- 2022-05-31 13:13 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by Checkmate Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-checkmate-pharmaceuticals-inc-amendment-2964285)
- 2022-05-31 12:38 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by Checkmate Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-checkmate-pharmaceuticals-inc-amendment-2963779)
- 2022-05-26 21:05 UTC [Market Insight] [Checkmate Pharmaceuticals To Report At ASCO Jun. 5](https://www.quantisnow.com/insight/checkmate-pharmaceuticals-to-report-at-asco-jun-5-2952707)
- 2022-05-20 20:37 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by Checkmate Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-checkmate-pharmaceuticals-inc-amendment-2924036)
- 2022-05-20 20:30 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by Checkmate Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-checkmate-pharmaceuticals-inc-amendment-2923887)
- 2022-05-17 21:12 UTC [SEC Form 4] [SEC Form 4: Venbio Global Strategic Fund Ii L.P. sold $1,375,564 worth of shares (131,650 units at $10.45)](https://www.quantisnow.com/insight/sec-form-4-venbio-global-strategic-fund-ii-lp-sold-2905336)
- 2022-05-13 00:47 UTC [SEC Form 4] [SEC Form 4: Venbio Global Strategic Fund Ii L.P. sold $1,671,824 worth of shares (160,901 units at $10.39)](https://www.quantisnow.com/insight/sec-form-4-venbio-global-strategic-fund-ii-lp-sold-2881123)
- 2022-05-12 21:06 UTC [Market Chatter] [Checkmate Pharmaceuticals Q1 EPS $(0.73) Down From $(0.65) YoY](https://www.quantisnow.com/insight/checkmate-pharmaceuticals-q1-eps-073-down-from-065-yoy-2880200)
- 2022-05-12 20:49 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Checkmate Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-checkmate-pharmaceuticals-inc-2879857)
- 2022-05-12 20:46 UTC [SEC Form 8-K] [Checkmate Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/checkmate-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-2879800)
- 2022-05-12 20:30 UTC [Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/checkmate-pharmaceuticals-announces-first-quarter-2022-financial-results-and-provides-2879344)
- 2022-05-11 21:11 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by Checkmate Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-checkmate-pharmaceuticals-inc-amendment-2871611)
- 2022-05-11 21:01 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by Checkmate Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-checkmate-pharmaceuticals-inc-amendment-2871484)
- 2022-05-11 18:57 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Checkmate Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-checkmate-pharmaceuticals-inc-amendment-2869643)
- 2022-05-09 22:58 UTC [SEC Form 4] [SEC Form 4: Venbio Global Strategic Fund Ii L.P. sold $898,921 worth of shares (86,677 units at $10.37)](https://www.quantisnow.com/insight/sec-form-4-venbio-global-strategic-fund-ii-lp-sold-2854899)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CMPI
- Earnings history: https://www.quantisnow.com/earnings/CMPI
- Dividend history: https://www.quantisnow.com/dividends/CMPI
- Insider transactions: https://www.quantisnow.com/insiders/CMPI
- Options chain: https://www.quantisnow.com/options/CMPI
- SEC 8-K filings only: https://www.quantisnow.com/company/CMPI/8-k
- RSS and alerts for CMPI: https://www.quantisnow.com/docs/rss-feeds.md